ChromaDex Corp CDXC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDXC is a good fit for your portfolio.
News
-
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
-
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
-
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
-
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
-
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
-
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
-
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
Trading Information
- Previous Close Price
- $1.33
- Day Range
- $1.37–1.42
- 52-Week Range
- $1.28–2.18
- Bid/Ask
- $1.37 / $1.40
- Market Cap
- $104.05 Mil
- Volume/Avg
- 89,901 / 78,138
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.19
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 113
- Website
- https://www.chromadex.com
Valuation
|
Metric
|
CDXC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.65 |
Price/Sales | 1.19 |
Price/Cash Flow | 75.14 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CDXC
|
|---|---|
Quick Ratio | 1.66 |
Current Ratio | 2.43 |
Interest Coverage | — |
Quick Ratio
CDXC
Profitability
|
Metric
|
CDXC
|
|---|---|
Return on Assets (Normalized) | −2.76% |
Return on Equity (Normalized) | −5.43% |
Return on Invested Capital (Normalized) | −6.03% |
Return on Assets
CDXC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rmcn | $453.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rbbsdfk | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cktxwhl | $88.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Mbglj | $40.3 Bil | |
MRNA
| Moderna Inc | Nrsx | $30.1 Bil | |
ARGX
| argenx SE ADR | Rzstb | $26.1 Bil | |
BNTX
| BioNTech SE ADR | Jwb | $23.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rnjwyq | $20.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gxfxdc | $16.9 Bil | |
INCY
| Incyte Corp | Jgkdvrr | $12.0 Bil |